News | October 18, 2024
MedGenome completes 10 years in genomics in India
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
We now rank 3rd in pharmaceutical production by volume and 14th by value
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Subscribe To Our Newsletter & Stay Updated
